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Abstract: Atheromatous and thrombotic embolization during percutaneous coronary 
revascularization is a feared complication that may cause impaired myocardial reperfusion even 
with a patent epicardial vessel. The MGuard stent is a cobalt chromium bare metal stent with a 
porous net attached to its outer surface that has been designed to prevent thrombus fragmentation 
and distal embolization during stent implantation. This review summarizes the available evidence 
supporting the use of the MGuard stent in different scenarios such as lesions with high thrombus 
burden, saphenous vein graft interventions, coronary perforations, or carotid lesions.
Keywords: Coronary artery disease, myocardial infarction, coronary stent, complication, 
thrombus, no-reflow phenomenon
Introduction
Atheromatous and thrombotic embolization during percutaneous coronary  intervention 
(PCI) is a feared complication that may cause impaired myocardial reperfusion even with 
a patent epicardial vessel.1 Patients with acute coronary syndromes and those  undergoing 
PCI of saphenous vein graphs (SVGs) are at highest risk of distal  embolization, which 
frequently occurs after stent implantation due to thrombus  fragmentation and protrusion 
by the stent struts. Inadequate myocardial  reperfusion may occur in up to 50% of cases 
despite the use of optimal evidence-based  coronary  revascularization and is associated 
with a worse in-hospital and long-term prognosis.2
Prevention of embolization rather than treatment should be the way forward as 
 treatment is unlikely to succeed if no reflow is established. Thus, several  pharmacological 
and technical strategies have been tested to minimize the distal embolization risk.3  Distal 
protection devices failed to show reductions in infarct size or mortality in patients under-
going primary PCI,4 although they seem to improve angiographic and clinical outcomes 
in PCI of degenerated SVG.5 Similarly, catheter-based thrombus aspiration has been 
associated with controversial results; although early single-center studies suggested a 
potential benefit, recent trials have shown no reductions in infarct size or mortality.6,7
The concept of a stent covered with a membrane attached to its outer surface 
(to create a mechanical barrier to prevent thrombus fragmentation and filtration through 
the struts) has also been tested previously.8 However, covered stents, compared with 
bare metal stents, were associated with an increased risk of myocardial infarction, thus 
prohibiting their use in this scenario. Importantly, the barrier created by the membrane 
was related to delayed endothelization of the stent and also to side branch occlusion, 
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The MGuard stent is a novel bare metal stent with a 
porous net attached to its outer surface that has been designed 
to trap thrombus debris reducing distal embolization, while 
pores allow normal endothelization of the stent through 
the membrane. The purpose of this review is to summarize all 
the relevant literature available about the use of this device.
The MGuard stent
The MGuard™ stent consists of a balloon-expandable close-
cell design bare metal stent with a polyethylene terephthalate 
microfiber sleeve attached to its outer surface (Figure 1). The 
first-generation stent used a 316L stainless steel frame with 
strut thickness of 100 µm, while the new MGuard™ Prime 
platform is manufactured of L605 cobalt chromium alloy 
(strut thickness 80 µm). The Micronet™ is identical on both 
stents, with a fiber width of 20 µm and an expanded aperture 
size of 150×180 µm.10 Thus, the net creates  custom-designed 
pores that are 5- to 40-fold smaller than the stent cells and 
appears to effectively act as a mechanical barrier decreasing 
or even preventing the thrombus protrusion and  embolization 
to the distal vessel.11 MGuard™ and MGuard™ Prime 
 diameters range from 2.5 mm to 4.0 mm, while lengths range 
from 11 to 39 and 13 to 38 mm, respectively.
Technical considerations
Guiding catheter, deliverability,  
and stent dislodgement
The MGuard stent is compatible with 0.014 in guide wires and 
6 Fg guiding catheters. Crossing profile is slightly higher than 
newer-generation bare metal stents (1.1–1.3 mm for the  stainless 
steel platform and 1.0–1.2 mm for the cobalt  chromium plat-
form), which together with the close-cell design may impair the 
deliverability. In a recent trial, the MGuard stent was unable to 
reach or cross the culprit lesion in nine of 217 cases (4.1%).12 
Of note, all nine cases occurred with the stainless steel platform. 
Similarly, a recent single-center experience reported 1.8% of 
cases in which the stent could not reach the lesion.13
From January 2011 to April 2014, the manufacturer 
received 54 complaints of stent dislodgement from the deliv-
ery system, most occurring with the MGuard Prime stent. By 
contrast, no cases of net detachment from the stent were seen. 
Stent dislodgement was reported in two of 217 cases (0.9%) 
of the prospective, randomized, multicenter evaluation of 
a polyethylene terephthalate micronet mesh–covered stent 
(MGuard) in ST-segment elevation myocardial infarction 
(MASTER) trial.12 Similarly, stent dislodgement occurred 
in six of 155 cases with the MGuard Prime stent (3.87%) 
at the IDE-MGuard for acute ST-elevation reperfusion II 
(MASTER II) trial,14 which led the manufacturer in 2014 
to a voluntary field safety corrective action. This included 
the temporary suspension of the MASTER II trial and the 
addition of a new step during the manufacturing process so-
called thermoforming in which the balloon-shaping process 
forms “shoulders,” which are intended to provide additional 
securement of the stent to the delivery system.
Side branch occlusion
Due to its double-layer design (metallic platform + mesh 
sleeve fibers), the MGuard stent may increase the risk of 
side branch (SB) occlusion. SB compromise may be related 
to two mechanisms: first, the summation of both layers (the 
metallic struts and the sleeve fibers) may act as a mechani-
cal barrier blocking the coronary flow to the SB; second, the 
thrombus nearly located to the bifurcation may shift from the 
main vessel to the SB. It is possible that SBs compromised 
by the second mechanism could slightly improve with phar-
macological treatment. Nevertheless, if the occluded SB is 
clinically relevant, a bifurcation technique may be considered 
(Figure 2). In our experience, wiring the SB should not be 
extremely complicated. By contrast, to advance a balloon 
across the net may require additional support measures such 
as the use of extension catheters.
MGuard stent in patients  
with ST-segment elevation 
myocardial infarction
After promising preliminary results in two small studies, effi-
cacy and safety of the MGuard stent in patients undergoing 
primary PCI were first assessed by Piscione et al15 (Table 1). 
This was a multicenter Italian prospective registry that 
included 100 patients with ST-segment elevation myocardial 
infarction (STEMI). Thrombectomy was performed in 10% 
of the patients and predilation in 42% of cases. Complete 
myocardial reperfusion including myocardial blush grade =3 
and ST-segment resolution at 60 minutes was achieved in 90% 
Figure 1 MGuard stent crimped onto a balloon.
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The MGuard coronary stent
of patients. In hospital mortality occurred in seven patients 
(five presenting with cardiogenic shock preprocedure). 
Two subacute stent thromboses were also reported. Major 
adverse cardiovascular events (MACEs) up to 2 years were 
observed in 7.9% of the patients. Similarly, the MAGICAL 
study was a prospective multicenter international trial that 
enrolled 60 consecutive patients with STEMI.16 In this study, 
a high rate of complete epicardial and myocardial perfusion 
was also achieved (thrombolysis in myocardial infarction 
[TIMI] 3 flow in 93% of patients, myocardial blush grade 3 
in 73%, ST-segment resolution in 68%). Cardiac mortality 
up to 3 years was very low (7%).17
As opposed to previous studies in whom manual aspira-
tion was performed in ,20% of cases, our group first reported 
results of the MGuard stent in selected cases of failed manual 
aspiration.13 The study included 56 consecutive patients in 
whom a high thrombus burden persisted after aggressive 
manual aspiration. After MGuard stent deployment, .89% 
of cases had thrombus score =0, and .70% ST resolution 
was observed in 58.7% of patients. Only one stent throm-
bosis (acute) was reported, and 9-month MACE rate was 
very low (3.6%).
Importantly, a recent retrospective study compared results 
of consecutive procedures performed with either bare metal 
stents or MGuard stents.18 Due to differences in baseline 
characteristics between groups, a propensity matching 
was performed. After adjustment, patients treated with the 
MGuard stent presented with restenosis more frequently than 
those treated with bare metal stents. These results, however, 
have not been confirmed in other recent studies.19
Two large-scale randomized trials have compared the 
MGuard stent to conventional PCI. The MASTER I trial 
was a prospective, multicentre, international, randomized 
study in which 433 subjects presenting with STEMI were 
randomized in a 1:1 fashion to the MGuard stent versus bare 
metal or drug-eluting stents.12 Device success was greater in 
the control arm (95.9% for MGuard vs 99.1% for control; 
P=0.003), but better reperfusion indices were obtained in 
the study group, as shown by the primary endpoint of the 
study, ST segment resolution (57.8% vs 44.7%; P=0.008), 
and incidence of TIMI 3 flow (91.7% vs 82.9%, P=0.006). 
Consequently, mortality at 30 days (0% vs 1.9%, P=0.06) 
and 1 year (1% vs 3.3%, P=0.09) tended to be lower in 
the MGuard group. Subgroup analyses showed the highest 
differences favoring the MGuard stent in cases with large 
thrombus burden20 or long delay time.21 However, incidence 
of repeat revascularization was higher than the control group 
(8.6% vs 0.9%, P=0.0003).22 The MASTER II trial was an 
international, multicenter, randomized trial designed to enrol 
1,114 patients to show superiority of the MGuard stent vs 
Figure 2 Coronary angiogram (30° cranial oblique projection) showing a totally occluded right coronary artery before intervention (A). Despite exhaustive thrombus 
aspiration. Red arrow points to the thrombotic total occlusion. (B), a high thrombus burden (TiMi thrombus score =4) persisted at the bifurcation (red arrows). After 
MGuard deployment (green line), TiMi 3 flow was restored to the posterolateral branch, although the posterior descending artery persisted totally occluded (C). Following 
“reverse T stenting,” final TIMI flow was 3 in both the posterior descending artery and the posterolateral branch branches (D, final result).
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conventional PCI in clinical events such as death or myo-
cardial infarction. However, due to a higher than expected 
frequency of stent dislodgement, the study was voluntarily 
suspended in April 2014 after enrolment of 310 patients (155 
patients per group). Analysis of the enrolled cohort showed no 
benefit of the MGuard stent in any of the analysed endpoints 
(ST-segment resolution was 56.9% vs 59.3% in the control 
group, P=0.68; mortality was 0.6% vs 1.9% in the control 
group, P=0.62).14 Similarly, a pooled analysis of the MAS-
TER I and II trials (n=743) failed to show better myocardial 
reperfusion (ST-segment resolution 57.5% for the MGuard 
vs 50.7% for the control group, P=0.07), although mortality 
at 30 days was lower (0.3% vs 1.9%, P=0.03).14
Thus, data from randomized trials suggest that the use 
of MGuard stent may reduce distal embolization and may 
improve survival at 30 days compared with other commer-
cially available coronary stents, although further random-
ized studies are warranted to confirm this hypothesis. Also, 
further research is needed to understand if the restenosis rate 
is only related to the lack of drug elution or, by contrast, if 
there is also an antigenic stimulus caused by the polyethylene 
terephthalate mesh.23
MGuard stent in saphenous  
vein grafts
Compared with atherosclerotic plaques in native coronary 
arteries, SVG plaques are softer, longer, more friable, and 
contain necrotic debris and cholesterol crystals. Thus, per-
cutaneous revascularization of SVG is associated with high 
rates of distal embolization, no-reflow phenomena, and 
periprocedural myocardial infarction. To avoid this com-
plication, several drugs and devices have been tested. Graft 
stents have shown discouraging results and distal protection 
devices, although effective, are associated with an increase 
of procedural length and costs.24,25
The performance of the MGuard stent has been tested 
in two small multicenter prospective registries. The first-in-
man study included 29 patients (17 with SVG intervention, 
mean SVG age =12.6 years).26 Device and procedural suc-
cess was 100%. Final TIMI 3 flow was observed in all cases, 
and periprocedural myocardial infarction was observed in a 
single case. However, an extension of the study with 23 SVG 
interventions showed a high rate of MACE (23%), although 
no stent thrombosis or cardiac deaths were observed up to 
20 months of follow-up.27 Similarly, the INSPIRE trial28 
reported a high rate of procedural success of the MGuard 
stent in 16 SVGs, achieving final TIMI 3 flow in all cases. 
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The MGuard coronary stent
frequency of repeated revascularization of the target vessel 
was observed at 12 months of follow-up (19%).
MGuard stent in other scenarios
Coronary perforations
Graft stents seem to be an effective tool to seal severe 
perforations that have persisted despite prolonged balloon 
inflation. However, the high profile and low flexibility of pre-
vious covered stents compromise the deliverability of these 
devices, particularly in emergency situations.9 Moreover, 
the mechanical barrier created by the membrane may pre-
clude the endothelization of the stent, which eventually may 
be associated with stent thrombosis or with restenosis at 
the stent edges. Our experience, although limited, suggests 
that the MGuard stents can also be successfully used to seal 
coronary perforations.29 The net, although pored, appears to 
effectively act as a mechanical barrier, decreasing or even 
preventing the leakage to the pericardial cavity. Nevertheless, 
additional mechanism might be involved, such as the stretch-
ing of the vessel or the compression of the disrupted tissue. 
Moreover, the cobalt chromium platform would be more 
deliverable than the graft stent allowing also successful 
deployment in tortuous vessels, whereas the porous net 
would allow endothelization of the stent. Importantly, when 
MGuard stents are used in this bailout situation, high rates 
of restenosis may be expected. The mechanism, although 
unknown, might also be related to the inflammatory process 
involving the perforation.
Coronary aneurysms
Coronary artery aneurysms are a rare condition with a 
reported incidence of 0.14%–4.9% of patients undergoing 
coronary angiography and 0.3%–5.3% in patients after PCI. 
The majority of coronary aneurysms are atherosclerotic in 
origin and, in most cases, they are asymptomatic. However, 
potential complications associated with these abnormali-
ties include thrombus formation, distal embolization, and, 
rarely, rupture.
Current available evidence for MGuard stent is limited 
to two case reports,30,31 in which the MGuard stent was suc-
cessfully implanted, achieving complete exclusion of the 
aneurysm. However, the percutaneous exclusion of coronary 
aneurysm is not generally recommended, and therefore 
the use of the MGuard stent in this scenario should not be 
advised. Moreover, in our experience, although limited to 
two cases, MGuard stent implantation did not achieve total 
exclusion of the aneurysm in the early phase and was related 
to severe restenosis at late follow-up.
Carotid arteries
To avoid microembolization after stent implantation in carotid 
artery stenosis, a mesh-covered stent may be implanted. 
Notably, for carotid arteries, the manufacturer has mounted 
the same porous net over a nitinol self-expandable platform 
(so-called CGuard stent). Although the clinical experience is 
very limited, recent results of the CARENET trial have shown 
a very low rate of new ischemic ipsilateral lesions (as assessed 
by diffusion-weighted magnetic resonance imaging) as well 
as no major adverse cardiac and cerebrovascular events at 30 
days.32 However, although these results are promising, more 
data are needed before making recommendations about the 
safety/efficacy of this device.
Perspectives
Considering the clinical benefits associated with drug-eluting 
stents in patients with STEMI and also due to the relatively 
high rate of restenosis of the MGuard stent, the manufacturer 
decided in 2014 to definitely cancel the MASTER II trial 
and to start development of the drug-eluting version of the 
MGuard stent. This new device will elute sirolimus from 
the stent platform (rather than the net) and will be available 
in late 2015.
Conclusion
The MGuard stent is a useful tool to avoid distal emboliza-
tion during PCI of thrombotic lesions. The micronet attached 
to its outer surface prevents thrombus fragmentation and 
filtration during stent deployment. The enhanced myocardial 
reperfusion achieved with the use of the MGuard stent may 
be associated with a reduced mortality compared with other 
commercially available bare metal or drug-eluting stents. 
However, its use is associated with some limitations that must 
be highlighted: 1) the stent deliverability (even with the cobalt 
chromium version) may be slightly worse than other coronary 
stents that may be related to a higher crossing profile, and it 
must be taken into account when treating severely calcified 
or tortuous vessels; 2) due to its double-layer design (metal-
lic platform + mesh sleeve fibers), the MGuard stent may 
compromise side branches, although bifurcation techniques 
can be performed to recover the compromised side branch; 
and 3) restenosis rate may be higher than with other com-
mercially available coronary stents.
The MGuard stent can also be used in SVGs when con-
ventional PCI with distal protection devices cannot be per-
formed, as well as to seal coronary perforations that persist 
despite prolonged balloon inflation. In these cases, however, 
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The new sirolimus-eluting version of the MGuard stent, which 
is currently under development, is invented to minimize the 
restenosis rate of the MGuard Prime stent and will probably 
be available in late 2015 in Europe.
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